Biotech Stocks on Investors' Radar -- Curis, Egalet, Esperion Therapeutics, and GlycoMimetics
NEW YORK, November 2, 2017 /PRNewswire/ --
If you want a Stock Review on CRIS, EGLT, ESPR, or GLYC then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. On Wednesday, November 01, 2017, US markets saw five out of nine sectors finishing the day in green and four in red. Major US indices were also mixed at the close of yesterday's session. The NASDAQ Composite ended the day at 6,716.53, down 0.17%; the Dow Jones Industrial Average edged 0.25% higher, to finish at 23,435.01; and the S&P 500 closed at 2,579.36, up 0.16%. This Thursday morning, DailyStockTracker.com looks at the performance of these four Biotechnology stocks: Curis Inc. (NASDAQ: CRIS), Egalet Corp. (NASDAQ: EGLT), Esperion Therapeutics Inc. (NASDAQ: ESPR), and GlycoMimetics Inc. (NASDAQ: GLYC). This morning's free research reports on the aforesaid equities can be accessed upon registration on DailyStockTracker.com at: http://dailystocktracker.com/register/
Curis
On Wednesday, shares in Lexington, Massachusetts headquartered Curis Inc. recorded a trading volume of 639,138 shares. The stock ended the session 3.80% lower at $1.52. The Company's shares have gained 2.01% over the previous three months. The stock is trading below its 50-day moving average by 11.44%. Moreover, shares of Curis, which engages in the discovery and development of drug candidates for the treatment of human cancers in the US, have a Relative Strength Index (RSI) of 34.65.
On October 24th, 2017, research firm Guggenheim initiated a 'Buy' rating on the Company's stock, with a target price of $7 per share. Visit us today and download your complete report on CRIS for free at: http://dailystocktracker.com/registration/?symbol=CRIS
Egalet
Wayne, Pennsylvania headquartered Egalet Corp.'s stock closed the day 4.18% lower at $0.94 with a total trading volume of 758,845 shares, which was above their three months average volume of 470.71 thousand shares. The stock is trading below its 50-day moving average by 23.27%. Additionally, shares of Egalet, which develops, manufactures, and commercializes treatments for patients with pain and other conditions, have an RSI of 29.50. The complimentary research report on EGLT can be accessed at: http://dailystocktracker.com/registration/?symbol=EGLT
Esperion Therapeutics
Shares in Ann Arbor, Michigan headquartered Esperion Therapeutics Inc. recorded a trading volume of 667,176 shares, which was above their three months average volume of 651.42 thousand shares. The stock ended yesterday's trading session 1.42% lower at $45.09. The Company's shares have advanced 342.49% in the past twelve months and 260.14% on an YTD basis. The stock is trading above its 200-day moving average by 16.24%. Furthermore, shares of Esperion Therapeutics, which focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol, have an RSI of 38.26. Register for free on DailyStockTracker.com and download the research report on ESPR at: http://dailystocktracker.com/registration/?symbol=ESPR
GlycoMimetics
Rockville, Maryland headquartered GlycoMimetics Inc.'s stock finished Wednesday's session 2.61% lower at $11.20 with a total trading volume of 836,569 shares, which was above their three months average volume of 471.03 thousand shares. The Company's shares have advanced 84.82% in the past twelve months and 83.61% since the start of this year. The stock is trading above its 200-day moving average by 21.90%. Additionally, shares of GlycoMimetics, which focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the US, have an RSI of 45.19. Get free access to your research report on GLYC at: http://dailystocktracker.com/registration/?symbol=GLYC
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected] . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://dailystocktracker.com/disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE dailystocktracker.com
Share this article